NCT00146380View on ClinicalTrials.gov

A Study of Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Reduction of Mother-to-child HIV Transmission During Breastfeeding

PHASE2CompletedINTERVENTIONAL
Enrollment

520

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2013

Conditions
HIV Infections
Interventions
DRUG

Zidovudine/Lamivudine and either Nevirapine or Nelfinavir

"Zidovudine 300mg po bid from 34 weeks gestation to 6 months postpartum Lamivudine 150mg po bid from 34 weeks gestation to 6 months postpartum AND EITHER Nevirapine 200mg po qd for 2 weeks as lead in then bid from 34 weeks gestation to 6 months postpartum OR Nelfinavir 1250mg po bid from 34 weeks gestation to 6 months postpartum~ARVs continued for those that meet WHO treatment criteria"

BEHAVIORAL

Breastfeeding for 6 months postpartum

Exclusive breastfeeding till five and one half months with rapid weaning over 2 weeks and cessation of breastfeeding at 6 months when ARVs are discontinued

Trial Locations (1)

Unknown

CDC Clincical Research Center, Kisumu

All Listed Sponsors
lead

Centers for Disease Control and Prevention

FED

NCT00146380 - A Study of Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Reduction of Mother-to-child HIV Transmission During Breastfeeding | Biotech Hunter | Biotech Hunter